Tusamitamab ravtansine
Based on 1 publication(s) in Google Scholar
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.50%
- CAS 番号: 2254086-60-5
- 分子量:148000 (average)
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-P99681
Labetuzumab govitecanAnti-CEACAM5 ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-132254A
Sacituzumab govitecan (solution)Trop-2 ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-P99016A
Enfortumab vedotin-ejfvNectin-4 ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC
MedChemExpress（MCE）の使用を引用している文献 Tusamitamab ravtansine
More
生物活性
製品説明
体外実験
The antibody component of SAR408701 binds to the extracellular domain of CEACAM5, initiating the internalization of the ADC into the tumor cell, followed by the subsequent release of DM4 within the cytoplasm. DM4 elicits its cytotoxic effects by disrupting microtubule assembly, inducing cell cycle arrest, and initiating apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2254086-60-5
-
性状 Liquid
-
分子量 148000 (average)
-
Color Colorless to light yellow
-
SMILES
[Tusamitamab ravtansine]
-
別名
SAR-408701; HuMAb2-3-SPDB-DM4
-
輸送条件
Shipping with dry ice.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Lorenzo Belluomini, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel). 2023 Nov 10;15(22):5368. [Content Brief]
[2]. Ye-Jin Kim, et al. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023 Feb 27:13:1124039. [Content Brief]
[3]. Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Tusamitamab ravtansine 関連分類
HY-P99542 関連分類
Powered by Bioz